Cargando…

The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine

BACKGROUND: Capecitabine is the most widely used agent for maintenance chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC). However, there are no biomarkers for identifying mTNBC patients who could benefit from capecitabine maintenance. METHODS: The prognostic roles of cyt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yiping, Li, Kai, Zhang, Jieling, Wang, Lu, Sheng, Lili, Yan, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798347/ https://www.ncbi.nlm.nih.gov/pubmed/35116447 http://dx.doi.org/10.21037/tcr-20-1760

Ejemplares similares

Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance
por: Lu, Shaolei, et al.
Publicado: (2019)

Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
por: Si, W., et al.
Publicado: (2013)

Cytokeratin 7-positive/cytokeratin 20-negative cecal adenocarcinoma metastatic to the uterine cervix: a case report
por: Toyoshima, Masafumi, et al.
Publicado: (2016)

Sialyl Lewis(X/A) and Cytokeratin Crosstalk in Triple Negative Breast Cancer
por: Pascoal, Carlota, et al.
Publicado: (2023)

EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
por: Serrano, Maria J., et al.
Publicado: (2014)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Cytokeratin expression in epidermal stem cells in skin adnexal tumors
por: Zhou, Xiaoqiu, et al.
Publicado: (2019)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Clinical significance of cytokeratin 19 and OCT4 as survival markers in non-metastatic and metastatic breast cancer patients
por: Abdelaziz, Lobna A., et al.
Publicado: (2022)

Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
por: Wang, Feng, et al.
Publicado: (2014)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer
por: Luo, Hai-Tao, et al.
Publicado: (2017)

Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis
por: Cen, Dong, et al.
Publicado: (2017)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Cytokeratin-negative small cell lung carcinoma
por: Terada, Tadashi
Publicado: (2011)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Clinical and Prognostic Significances of Cytokeratin 19 and KIT Expression in Surgically Resectable Pancreatic Neuroendocrine Tumors
por: Son, Eun-Mi, et al.
Publicado: (2015)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

Prognostic significance of GSTP1 in patients with triple negative breast cancer
por: Chen, Guanglei, et al.
Publicado: (2017)

Expression and Prognostic Significance of BANF1 in Triple-Negative Breast Cancer
por: Zhang, Genhao
Publicado: (2020)

Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer
por: Cao, Jintao, et al.
Publicado: (2021)

Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer
por: Čeprnja, Toni, et al.
Publicado: (2022)

Cytokeratin-Positive Osteosarcoma Simulating Sarcomatoid Metastatic Carcinoma
por: Murtaza, Hamza, et al.
Publicado: (2020)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

The Significance of Caspase-Cleaved Cytokeratin 18 in Pleural Effusion
por: Lee, Keu Sung, et al.
Publicado: (2014)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience
por: Guo, Qiaojuan, et al.
Publicado: (2020)

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
por: Chen, Xue-Lian, et al.
Publicado: (2016)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer
por: jarroudi, O Al, et al.
Publicado: (2019)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
por: Kessler, Alaina J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_40p8s99m29cf85govpj1r0f8uv